Amicus Therapeutics, Inc. (FOLD) rallied sharply during US trading, climbing over 30% to trade around USD 14.20, as investors reassessed the company’s earnings trajectory and revenue growth profile. The move comes amid a broader improvement in equity risk sentiment, where investors have shown renewed willingness to reprice growth-oriented stocks with clearer paths to profitability.

Strong Price Action Reflects Reassessment of Fundamentals

The outsized move in FOLD follows growing confidence in the company’s underlying financial performance. Amicus reported Q2 FY25 revenue of USD 154.69 million and positive earnings of USD 1.93 million, reinforcing the view that its commercial portfolio is scaling more efficiently. The stock also reached the upper end of its 52-week range, signaling a decisive shift in market positioning.

Intraday trading showed sustained buying interest rather than a short-lived spike, with volume surging far above its historical average. This pattern suggests participation from institutional investors reassessing valuation rather than purely speculative flows. The company’s market capitalization of approximately USD 4.38 billion now reflects expectations of accelerating revenue growth into 2026.

Earnings Outlook and Analyst Expectations in Focus

Analyst forecasts point to continued momentum. For FY2025, average earnings estimates stand at USD 0.38 per share, rising to USD 0.66 in FY2026. Revenue is expected to increase from an estimated USD 629 million this year to nearly USD 745 million next year, implying high-teens growth.

While Amicus has delivered mixed earnings surprises in recent quarters, the most recent upside surprise has helped stabilize confidence. Importantly, growth estimates for the coming year significantly exceed broader market averages, highlighting why the stock has regained attention among growth-focused investors despite its biotech risk profile.

Market Resonance, Energy Costs, and Risk Sentiment

The rally in Amicus also occurred against a backdrop of shifting cross-asset dynamics. Recent moves in oil prices have influenced equity sentiment more broadly, with energy cost stability easing pressure on inflation expectations. This environment has supported risk assets, particularly in sectors such as biotechnology that are sensitive to funding conditions and discount-rate assumptions.

Energy stocks and transport names have remained relatively steady, helping maintain broader market balance. For Israeli investors, the move in Amicus resonates with sentiment toward innovative healthcare and life-sciences firms, a segment where Israel maintains strong global exposure through biotech research and medical technology development.

Looking ahead, investors will closely monitor upcoming earnings updates, prescription growth trends, and margin progression to assess whether the current repricing can be sustained. Risks remain, including execution challenges, competitive pressures, and sensitivity to broader market volatility. Opportunities may emerge if revenue growth continues to outperform expectations and operating leverage improves. After the latest surge, Amicus Therapeutics has re-entered the spotlight as a name where fundamentals and sentiment are rapidly converging.